within Pharmacolibrary.Drugs.ATC.R;

model R03DX05
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 3.9999999999999996e-05,
    adminDuration  = 600,
    adminMass      = 150 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.00747,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.00432,
    k12             = 0.393,
    k21             = 0.393
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>R03DX05</td></tr><td>route:</td><td>subcutaneous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Omalizumab is a humanized monoclonal antibody that selectively binds to immunoglobulin E (IgE). It is primarily used as an add-on therapy for moderate to severe persistent allergic asthma not adequately controlled with inhaled corticosteroids. Omalizumab is also approved for treatment of chronic spontaneous urticaria. The drug is administered subcutaneously and is approved in the United States, Europe, and many other countries.</p><h4>Pharmacokinetics</h4><p>Population pharmacokinetics in adult and adolescent patients with moderate to severe allergic asthma after subcutaneous administration.</p><h4>References</h4><ol><li><p>Luu, M, et al., &amp; Goirand, F (2016). Pharmacokinetics, pharmacodynamics and clinical efficacy of omalizumab for the treatment of asthma. <i>Expert opinion on drug metabolism &amp; toxicology</i> 12(12) 1503–1511. DOI:<a href=\"https://doi.org/10.1080/17425255.2016.1248403\">10.1080/17425255.2016.1248403</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/27748630/\">https://pubmed.ncbi.nlm.nih.gov/27748630</a></p></li><li><p>Bang, LM, &amp; Plosker, GL (2004). Omalizumab: a review of its use in the management of allergic asthma. <i>Treatments in respiratory medicine</i> 3(3) 183–199. DOI:<a href=\"https://doi.org/10.2165/00151829-200403030-00006\">10.2165/00151829-200403030-00006</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/15219177/\">https://pubmed.ncbi.nlm.nih.gov/15219177</a></p></li><li><p>Labrador-Horrillo, M, &amp; Ferrer, M (2015). Profile of omalizumab in the treatment of chronic spontaneous urticaria. <i>Drug design, development and therapy</i> 9 4909–4915. DOI:<a href=\"https://doi.org/10.2147/DDDT.S56004\">10.2147/DDDT.S56004</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/26346472/\">https://pubmed.ncbi.nlm.nih.gov/26346472</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end R03DX05;
